1,721,519 research outputs found
Workshop on transformation products of emerging pollutants in the aquatic environment (TREMEPOL project)
No full textAnchoring the chronology of amphora stamps from Herakleia Pontica
Full text linkTransport amphoras from Herakleia Pontica are common finds at sites around the Black Sea. Their stamped fragments are essential for dating 4th-century-BC archaeological deposits in the region. Despite various challenges that have hindered the development of a reliable chronology of the Herakleian stamps in the past, recent advancements have been made in establishing the sequence of magistrates mentioned on them. However, the absence of historically fixed points has made it difficult to firmly anchor this sequence in time, leading to considerable uncertainty about the dates of the officials’ terms. This article proposes a solution based on two settlements on the west Black Sea coast. The evidence suggests that these settlements were abandoned after being attacked by Philip II’s armies in 339 BC. This event serves as a historical terminus ante quem for the terms of multiple Herakleian magistrates whose names appear on amphora stamps found at these sites. This allows for estimation of absolute dates for the magistrate list spanning the first three quarters of the 4th century
SAVE THE DATE: le 21/09/2023 à 18:00. Réflexions autour du livre de Claire Sotinel, Rome, la fin d’un empire. De Caracalla à Théodoric (212-fin du Ve siècle), École française d'Athènes
No full textVéronique Chankowski Directrice de l’EFA Introduction et présentation Claire Sotinel Université Paris-Est Créteil Rome, la fin d’un empire. De Caracalla à Théodoric (212-fin du Ve siècle) La présentation de l’ouvrage sera suivie des interventions de : Platon Petridis Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών / National & Kapodistrian University of Athens Kostis Smyrlis Ινστιτούτο Ιστορικών Ερευνών / National Hellenic Research Foundation Plus d'info ici Webinaire / Webinar En 212, ..
Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
No full textBreast cancer (BC) has historically been treated as a single disease entity; however, in the last decade, insights into its molecular heterogeneity have underpinned the development/commercialisation of several genomic tools whose goal is to guide patient management in early BC. These include the Oncotype DX Breast Recurrence ScoreTM assay, MammaPrint, Prosigna, and EndoPredict. Although these assays are similar in that they are all multigene assays reflecting risk of recurrence, they differ substantially in the technological platform used to measure gene expression; the number and identity of genes assessed; the patient populations used for development and validation; and the level of evidence supporting clinical utility. They also differ in the amount of evidence demonstrating their impact on treatment decisions and cost effectiveness in different countries. This review discusses these 4 assays, highlighting the clinical evidence that supports each of them, while focussing on the Recurrence Score assay. This assay has the greatest body of evidence supporting its clinical utility and decision impact/effectiveness, and currently is the only one validated as a predictor of response to adjuvant chemotherapy in hormone -receptor positive early BC patients treated with endocrine therapy and to be included as such in international/national BC treatment guidelines. The review also discusses ongoing prospective trials investigating the 4 assays, recent outcome studies, as well as analyses comparing different assays on the same tumour blocks. (C) 2016 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved
Length-weight relationships of nine common demersal Elasmobranch species from the Eastern Mediterranean
No full textLength-weight relationships were estimated for common demersal elasmobranch species in two different fishing regions - Northeastern Aegean Sea (NEAS) and North Eastern Levantine Sea (NELS) - in the Eastern Mediterranean. All individuals were collected using bottom trawl fishing vessels from September 2014 to April 2016. Nonlinear models were used and the values of parameter b of the length-weight relationship W = aL(b) ranged from 2.2931 to 3.4455 from NELS and 3.0519 to 3.2089 from NEAS. Notwithstanding that the total length measurements of Scyliorhinus canicula showed differences between NELS and NEAS, there were no significant differences according to the sampling periods and the depths in the study
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")
No full textBackground/Purpose APS ACTION Registry was created to study the outcomes of patients with persistently positive antiphospholipid antibodies (aPL) with or without other systemic autoimmune disease (SAIDx). Given that immunosuppression (IS) is used for certain aPL manifestations, for example, thrombocytopenia (TP), our primary objective was to describe the indications for IS in aPL-positive patients without other SAIDx. Secondly, we report the type of IS used in patients with selected microvascular or non-thrombotic aPL manifestations. Methods An online database is used to collect clinical data. The inclusion criteria are positive aPL based on the laboratory section of the APS Classification Criteria, tested at least twice within one year prior to enrollment. Patients are followed every 12 +/- 3 months. For this descriptive retrospective and prospective analysis, we included aPL-positive patients without other SAIDx and excluded those with new SAIDx classification during follow-up. For each patient, we retrieved clinical data at baseline and follow-up including selected aPL manifestations (diffuse alveolar hemorrhage [DAH], antiphospholipid-nephropathy [aPL-N], livedoid vasculopathy [LV]-related skin ulcers, TP, autoimmune hemolytic anemia [AIHA], cardiac valve disease [VD]), and IS medications. Results Of 899 patients enrolled, 537 were included in this analysis (mean age 45 +/- 13 years, female 377 [70%], APS Classification in 438 [82%], and at least one selected microvascular or non-thrombotic aPL manifestation in 141 (26%)). Of 537 patients, 76 (14%) were reported to use IS (ever), and 41/76 (54%) received IS primarily for selected aPL manifestation. In six of 8 (75%) DAH patients, 6/19 (32%) aPL-N, 4/28 (14%) LV, 25/88 (28%) TP, 6/11 (55%) AIHA, and 1/43 (2%) VD, the IS (excluding corticosteroids/hydroxychloroquine) indication was specific for selected aPL manifestation. Conclusion In our international cohort, 14% of aPL-positive patients without other SAIDx were reported to receive IS; the indication was at least one of the selected microvascular and/or non-thrombotic aPL-related manifestations in half. Thrombocytopenia was the most frequent among those selected aPL-related manifestations; however, approximately one-third received IS specifically for that indication. Diffuse alveolar hemorrhage was frequently treated with IS followed by AIHA and aPL-N. Systematic controlled studies are urgently needed to better define the role of IS in APS
EMAS position statement: diet and health in midlife and beyond
No full textIntroduction: There is increasing evidence that life-style factors, such as nutrition, physical activity, smoking and alcohol consumption have a profound modifying effect on the epidemiology of most major chronic conditions affecting midlife health
- …
